Related Experiment Videos
Effect of platelet-activating factor antagonist on brain injury in rats
T Tokutomi1, M Sigemori, T Kikuchi
1Department of Neurosurgery, Kurume University School of Medicine, Japan.
Abstract:
The ability of a platelet-activating factor (PAF) antagonist to reduce infarct size has been reported in a animal model of focal brain ischemia. The authors studied the effect of PAF antagonist (TCV-309) on cold brain injury in rats. Twenty-four hours after injury, water content was determined by both drying-weighing and specific gravimetric techniques, and ischemic brain damage was assessed with 2,3,5-triphenyltetrazolium chloride in multiple coronal sections. Pretreatment with TCV-309 (lmg/kg) significantly reduced the water content (p < 0.01) and volume of ischemic damage (p < 0.001) produced by the cold brain injury. These results indicate that PAF antagonist can ameliorate secondary brain tissue damage following brain injury.
Insights
Platelet-activating factor (PAF) antagonists, like TCV-309, significantly reduce brain tissue damage and water content in rat models of cold brain injury. This suggests PAF antagonists can mitigate secondary brain damage after injury.
Area of Science:
- Neuroscience
- Pharmacology
- Ischemic Stroke Research
Background:
- Platelet-activating factor (PAF) plays a role in inflammatory responses and tissue damage.
- Previous studies suggest PAF antagonists may reduce infarct size in focal brain ischemia models.
Purpose of the Study:
- To investigate the therapeutic effect of a novel PAF antagonist, TCV-309, on cold-induced brain injury in a rat model.
- To assess the impact of TCV-309 on secondary brain tissue damage and edema formation.
Main Methods:
- A cold injury model was established in rats.
- Animals were pretreated with TCV-309 (1 mg/kg).
- Brain water content was measured using gravimetric techniques, and ischemic damage volume was assessed via 2,3,5-triphenyltetrazolium chloride staining.
Main Results:
- TCV-309 pretreatment significantly reduced brain water content (p < 0.01).
- TCV-309 significantly decreased the volume of ischemic brain damage (p < 0.001).
Conclusions:
- PAF antagonist TCV-309 demonstrates neuroprotective effects in a cold brain injury model.
- These findings indicate that targeting PAF signaling pathways can ameliorate secondary brain tissue damage following acute brain injury.